Oncology is a broad term, but as far as eliciting immune response in tumor microenvironments, maybe. We will have to wait to find out, which is why I said if they can prove the aforementioned advantages in clinical trials...
On a side note, dismissing the work of the many scientists at OncoSec with years of big pharma/biotech experience by projecting their work as a one man show driven by PD is a bit unfair, IMO.
News 
Market Data 
Discover 
AI
